183 related articles for article (PubMed ID: 29396568)
1. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
2. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.
Yaghoubi A; Asgharzadeh F; Movaqar A; Ghazvini K; Hassanian SM; Avan A; Khazaei M; Soleimanpour S
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2851-2865. PubMed ID: 34117917
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.
Hu C; Chen X; Huang Y; Chen Y
Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453
[TBL] [Abstract][Full Text] [Related]
6. TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy.
Hao X; Yan Q; Zhao J; Wang W; Huang Y; Chen Y
PLoS One; 2015; 10(9):e0138911. PubMed ID: 26405806
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity.
Hao W; Hu C; Huang Y; Chen Y
PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065
[TBL] [Abstract][Full Text] [Related]
8. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
9. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model.
Gupta SK; Torrico Guzmán EA; Meenach SA
Int J Cancer; 2017 Nov; 141(10):2143-2153. PubMed ID: 28771722
[TBL] [Abstract][Full Text] [Related]
11. iRGD-mediated core-shell nanoparticles loading carmustine and O
Liu C; Yao S; Li X; Wang F; Jiang Y
J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474
[TBL] [Abstract][Full Text] [Related]
12. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
13. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
14. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
15. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
16. Core-shell nanocarriers with high paclitaxel loading for passive and active targeting.
Jin Z; Lv Y; Cao H; Yao J; Zhou J; He W; Yin L
Sci Rep; 2016 Jun; 6():27559. PubMed ID: 27278751
[TBL] [Abstract][Full Text] [Related]
17. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
18. Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD.
Fadeev R; Chekanov A; Solovieva M; Bezborodova O; Nemtsova E; Dolgikh N; Fadeeva I; Senotov A; Kobyakova M; Evstratova Y; Yakubovskaya R; Akatov V
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691192
[TBL] [Abstract][Full Text] [Related]
19. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
[TBL] [Abstract][Full Text] [Related]
20. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]